Preparation of α-emitting 213Bi-labeled antibody constructs for clinical use

Journal of Nuclear Medicine

Volumn 40, Issue 10, 1999, Pages 1722-1727

  McDevitt, Michael R ^a   Finn, Ronald D ^a   Ma, Dangshe ^a   Larson, Steven M ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

particles; 213Bi; HuM195; Monoclonal antibodies; Therapy

Indexed keywords

BISMUTH; MONOCLONAL ANTIBODY M 195; PENTETIC ACID DERIVATIVE; PYROGEN;

ALPHA RADIATION; ARTICLE; DRUG DETERMINATION; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; PRIORITY JOURNAL; RADIATION DOSE; THIN LAYER CHROMATOGRAPHY;

ACTINIUM; ALGORITHMS; ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; BISMUTH; CLINICAL TRIALS, PHASE I; HUMANS; ISOTOPE LABELING; LEUKEMIA, MYELOID; QUALITY CONTROL; RADIOISOTOPES;

EID: 0032888303     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55(suppl):5908s-5910s.
2. Kaspersen FM, Bos E, Doornmalen AV, Geerlings MW, Apostolidis C, Molinet R. Cytotoxicity of Bi-213 and Ac-225 immunoconjugates. Nucl Med Commun. 1995;16:468-476.
3. McDevitt MR, Nikula TN, Finn RD, et al. Bismuth labeled antibodies for therapy of leukemias, lymphomas, and carcinomas: preclinical studies [abstract]. Tumor Targeting. 1996;2:182.
4. Scheinberg DA, Jurcic JG, Caron PC, et al. Radioimmunotherapy of myeloid leukemias with anti-CD33 based agents [abstract]. Tumor Targeting. 1996;2:160.
5. Kennel SJ, Mirzadeh S. Vascular targeting for radioimmunotherapy with Bi-213. Radiochimica Acta. 1997;79:87-91.
6. McDevitt MR, Finn RD, Larson SM, et al. Bismuth-labeled antibodies for therapy of prostate carcinomas: preclinical studies [abstract]. J Nucl Med 1998;39:223P-224P.
7. Yang WH, Ballangrud AM, McDevitt MR, et al. Alpha particle emitter therapy of micrometastases: Bi-213-J591 (anti-PSMA) treatment of LNCaP spheroids [abstract]. Proc Am Assoc Can Res.1998;39:440.
8. Kennel SJ, Mirzadeh S. Vascular targeted radioimmunotherapy with Bi-213 - an α-particle emitter. Nucl Med Biol. 1998;25:241-246.
9. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting radionuclides. Eur J Nucl Med 1998;25:1341-1351.
10. Nikula TN, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40:166-176.
11. Finn RD, McDevitt MR, Scheinberg DA, et al. Refinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceutical. J Labelled Compds Radiopharm. 1997;40:293.
12. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Rad Isotopes. 1999;50:895-904.
13. van Geel JNC, Fuger JJ, Koch L, inventors. Method for producing actinium-225 and bismuth-213. US patent 5,355,394. October 11, 1994.
14. Methods for the production of Ac-225 and Bi-213 for alpha immunotherapy. ITU Annual Report 1995-(EUR 16368)-Basic Actiniae Research 1995:55-56.
15. Boll RA, Mirzadeh S, Kennel SJ. DePaoli DW, Webb OF. Bi-213 for alpha-particle-mediated radioimmunotherapy J Labelled Compds Radiopharm. 1997;40:341.
16. Brechbiel MW, Gansow OA. Synthesis of C-functionalised transcyclohexyldiethylenetri-aminepentaacetic acids for labeling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc Perkin Trans I. 1992:1173-1178.
17. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992;52:6761-6767.
18. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol. 1992;148:1149-1154.
19. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3:339-348.
20. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia. 1989;3:440-445.
21. Co MS, Scheinberg DA, Avdalovic NM, et al. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol Immunol 1993;30:1361-1367.
22. Jurcic JG, McDevitt MR, Sgouros G, et al. Targeted alpha particle therapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33) [abstract]. Blood. 1997;90(suppl):504a.
23. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol. 1995;22:387-390.
24. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjugate Chem. 1992;3:342-345.
25. Spivakov BY, Stoyanov ES, Gribov LA, Zolotov YA. Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions. J Inorg Nucl Chem. 1979;14:453-455.
26. Atcher RN, Friedman AM, Hines JJ. An improved generator for the production of Bi-212 and Bi-212 from Ra-224. Appl Radiat Isot. 1988;39:283-286.
27. Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science. 1982;215:1511-1513.
28. Vaughan ATM, Bateman WJ, Fisher DR. The in vivo fate of a At-211 labeled monoclonal antibody with known specificity in a murine system. Int J Rad Oncol Biol Phys. 1982;8:1943-1946.
29. Sgouros G, Humm JL, McDevitt MR. et al. Bismuth-213 imaging: pre-clinical characterization of an alpha-particle emitting radionuclide [abstract]. J Nucl Med. 1996;37:78P.
30. Sgouros G, Erdi YE, Humm JL, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled anti-CD33 antibody ([Bi-213]HuM195) in patients with leukemia [abstract]. J Nucl Med. 1997;38:231P.
31. Jurcic JG, McDevitt MR, Sgouros G, et al. Phase I trial of targeted alpha particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33). Paper presented at: American Society of Clinical Oncology; May 15-18, 1999; Atlanta, GA.